Lucas M - Search Results

1

Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Kay NE, et al. Among authors: lucas m. Hematology Am Soc Hematol Educ Program. 2002:193-213. doi: 10.1182/asheducation-2002.1.193. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446424 Review.

2

Rituximab in B-cell chronic lymphocytic leukemia.

Lin TS, Lucas MS, Byrd JC. Lin TS, et al. Semin Oncol. 2003 Aug;30(4):483-92. doi: 10.1016/s0093-7754(03)00239-2. Semin Oncol. 2003. PMID: 12939717 Review.

3

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.

Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC. Lin TS, et al. Blood. 2005 Jan 1;105(1):289-91. doi: 10.1182/blood-2004-02-0651. Epub 2004 Jun 24. Blood. 2005. PMID: 15217834 Free article. Clinical Trial.

4

Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.

Blum KA, Young D, Broering S, Lucas MS, Fischer B, Lin TS, Grever MR, Byrd JC. Blum KA, et al. J Clin Oncol. 2007 Dec 10;25(35):5624-9. doi: 10.1200/JCO.2007.12.1152. Epub 2007 Nov 5. J Clin Oncol. 2007. PMID: 17984187

5

Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.

Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC. Lin TS, et al. Among authors: lucas ms, lucas dm. Leuk Lymphoma. 2009 Dec;50(12):1977-82. doi: 10.3109/10428190903288464. Leuk Lymphoma. 2009. PMID: 19860624 Clinical Trial.

6

Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.

Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA. Lin TS, et al. Among authors: lucas ms. J Clin Oncol. 2010 Oct 10;28(29):4500-6. doi: 10.1200/JCO.2010.29.7978. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697069 Free PMC article. Clinical Trial.

7

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC. Lozanski G, et al. Among authors: lucas m, lucas d. Blood. 2004 May 1;103(9):3278-81. doi: 10.1182/blood-2003-10-3729. Epub 2004 Jan 15. Blood. 2004. PMID: 14726385 Free article.

8

Antibody therapy for chronic lymphocytic leukemia: a promising new modality.

Lin TS, Moran M, Lucas M, Waymer S, Jefferson S, Fischer DB, Grever MR, Byrd JC. Lin TS, et al. Among authors: lucas m. Hematol Oncol Clin North Am. 2004 Aug;18(4):895-913, ix-x. doi: 10.1016/j.hoc.2004.04.008. Hematol Oncol Clin North Am. 2004. PMID: 15325705 Review.

9

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Willis CR, Goodrich A, Park K, Waselenko JK, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC, Flinn IW. Willis CR, et al. Among authors: lucas m. Ann Hematol. 2006 May;85(5):301-7. doi: 10.1007/s00277-005-0025-9. Epub 2006 Mar 4. Ann Hematol. 2006. PMID: 16518606 Clinical Trial.

10

Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.

Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Kasamon YL, et al. Clin Cancer Res. 2005 Dec 1;11(23):8413-7. doi: 10.1158/1078-0432.CCR-05-1612. Clin Cancer Res. 2005. PMID: 16322303 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,887 results

Search Page